Skip to main content

Table 3 Effects of 3 months of 2-g n-3 PUFAs supplementation on metabolic status, inflammatory markers and resolvin D1

From: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes

Variables

Placebo

N = 38

n-3 PUFAs

N = 36

p value

HbA1c (%)

 Before

7.00 (6.50; 7.50)

7.00 (6.70; 7.48)

0.45

 After

6.80 (6.50; 7.35)

7.10 (6.90; 7.75)

0.06

Insulin (mU/mL)

 Before

22.30 (16.20; 33.63)

20.85 (12.85; 34.80)

0.59

 After

16.80 (12.83; 32.23)

22.35 (13.33; 39.58)

0.72

Peptide C (pmol/mL)

 Before

2.99 (2.10; 4.07)

3.27 (2.70; 4.11)

0.43

 After

2.87 (1.97; 4.03)

3.30 (2.41; 4.64)

0.15

TC (mmol/L)

 Before

3.53 (3.16; 4.21)

3.80 (3.25; 4.63)

0.50

 After

3.78 (3.25; 4.45)

3.50 (3.11; 4.35)

0.53

LDL-C (mmol/L)

 Before

1.84 (1.47; 2.48)

2.07 (1.62; 2.83)

0.51

 After

2.07 (1.71; 2.54)

1.81 (1.44; 2.59)

0.24

HDL-C (mmol/L)

 Before

1.23 (1.04; 1.56)

1.22 (0.90; 1.39)

0.45

 After

1.24 (0.99; 1.47)

1.19 (0.91; 1.56)

0.76

TG (mmol/L)

 Before

1.30 (0.95; 1.62)

1.79 (1.8; 2.41)

0.01

 After

1.41 (1.13; 1.72)

1.48 (0.91; 2.08)

0.69

Leptin (ng/mL)

 Before

5.66 (2.54; 9.14)

3.26 (1.21; 8.09)

0.09

 After

6.14 (3.02; 12.19)*

3.45 (1.35; 8.18)

0.01

Adiponectin (ng/mL)

 Before

4.03 (3.21; 6.35)

3.52 (2.32; 4.06)

0.01

 After

4.19 (3.20; 5.75)

3.26 (2.28;4.42)

0.03

hsCRP (mg/L)

 Before

1.71 (0.72; 3.10)

1.52 (0.76; 2.53)

0.73

 After

1.97 (0.98; 3.13)

1.75 (0.66; 3.73)

0.67

IL-6 (pg/mL)

 Before

2.03 (1.49; 3.32)

1.97 (1.57;2.38)

0.66

 After

1.95 (1.19; 3.76)

2.05 (1.69; 3.43)

0.50

TNF-α (pg/mL)

 Before

1.48 (1.29; 1.72)

1.51 (1.26; 1.84)

0.66

 After

1.47 (1.25; 1.86)

1.46 (1.21; 1.76)

0.73

sICAM-1/CD54 (ng/mL)

 Before

205.87 (169.4;258.7)

222.64 (168.2; 241.2)

0.94

 After

201.88 (168.0; 262.4)

208.27 (178.3; 271.6)

0.74

sVCAM-1/CD106 (ng/mL)

 Before

875.20 (659.8; 1385.0)

1138.2 (818.6; 1604.3)

0.11

 After

832.95 (638.3; 1515.0)

1275.3 (825.9; 1554.9)

0.06

Myeloperoxidase (ng/mL)

 Before

28.80 (18.43; 40.68)

40.46 (20.16; 55.57)

0.15

 After

28.24 (18.56; 44.92)

29.18 (24.21; 48.99)

0.60

RvD1 (pg/mL)

 Before

244.60 (150.1; 457.5)

237.40 (123.40; 469.0)

0.59

 After

232.85 (144.65; 409.4)

184.90 (106.08; 660.6)

0.74

  1. Data shown as number (percentage) for categorical variables and mean (±standard deviation) or median (IQR) for continuous variables
  2. HbA1c glycated hemoglobin, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, hsCRP high-sensitivity C-reactive protein, IL-6 interleukin-6, TNF-α tumor necrosis factor-α, ICAM-1 intercellular adhesion molecule-1, VCAM-1 vascular adhesion molecule-1, RvD1 resolvin D1
  3. * p = 0.01 within the placebo group